IntoCell

IntoCell, Inc. is a biotechnology company operator that plans to develop a new antibody-drug conjugate (ADC) for patients. The company's technology includes cleavable linker ortho-hydroxy protected aryl sulfates (OHPAS), proprietary payloads, and payload modification technology (PMT), focusing on the development and commercialization of novel ADCs. By incorporating scaffold fragments, ligands, toxins, linkers, and conjugation methods, it enables doctors to treat patients with unmet medical needs.